245 related articles for article (PubMed ID: 26443607)
21. CTLA-4 and TNF-α promoter-308 A/G polymorphisms and ANCA-associated vasculitis susceptibility: a meta-analysis.
Lee YH; Choi SJ; Ji JD; Song GG
Mol Biol Rep; 2012 Jan; 39(1):319-26. PubMed ID: 21553055
[TBL] [Abstract][Full Text] [Related]
22. Anti-neutrophil cytoplasmic antibody-associated vasculitis, large vessel vasculitis and Kawasaki disease in Japan.
Kobayashi S; Fujimoto S; Takahashi K; Suzuki K
Kidney Blood Press Res; 2010; 33(6):442-55. PubMed ID: 21071954
[TBL] [Abstract][Full Text] [Related]
23. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis.
Tsuchiya N; Kobayashi S; Kawasaki A; Kyogoku C; Arimura Y; Yoshida M; Tokunaga K; Hashimoto H
J Rheumatol; 2003 Jul; 30(7):1534-40. PubMed ID: 12858454
[TBL] [Abstract][Full Text] [Related]
24. Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis.
Simon A; Subra JF; Guilpain P; Jeannin P; Pignon P; Blanchard S; Garo E; Jaillon S; Chevailler A; Renier G; Puéchal X; Bottazzi B; Mantovani A; Delneste Y; Augusto JF
PLoS One; 2016; 11(1):e0147091. PubMed ID: 26797217
[TBL] [Abstract][Full Text] [Related]
25. New advances in the pathogenesis of ANCA-associated vasculitides.
Chen M; Kallenberg CG
Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S108-14. PubMed ID: 19646356
[TBL] [Abstract][Full Text] [Related]
26. [Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: advances in pathogenesis and treatment].
Silva F; Cisternas M
Rev Med Chil; 2013 Jun; 141(6):765-73. PubMed ID: 24121580
[TBL] [Abstract][Full Text] [Related]
27. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis.
Mahr A; Katsahian S; Varet H; Guillevin L; Hagen EC; Höglund P; Merkel PA; Pagnoux C; Rasmussen N; Westman K; Jayne DR;
Ann Rheum Dis; 2013 Jun; 72(6):1003-10. PubMed ID: 22962314
[TBL] [Abstract][Full Text] [Related]
28. [ANCA associated vasculitis has genetic components].
Weiss J
Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281533
[No Abstract] [Full Text] [Related]
29. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
Csernok E; Lamprecht P; Gross WL
Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.
Berti A; Cavalli G; Campochiaro C; Guglielmi B; Baldissera E; Cappio S; Sabbadini MG; Doglioni C; Dagna L
Semin Arthritis Rheum; 2015 Aug; 45(1):48-54. PubMed ID: 25841802
[TBL] [Abstract][Full Text] [Related]
31. Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.
Zheng Y; Zhang Y; Cai M; Lai N; Chen Z; Ding M
Front Neurol; 2018; 9():1166. PubMed ID: 30687221
[No Abstract] [Full Text] [Related]
32. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
Mohammad AJ; Segelmark M
J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and diagnosis of otitis media with ANCA-associated vasculitis.
Yoshida N; Iino Y
Allergol Int; 2014 Dec; 63(4):523-32. PubMed ID: 25339433
[TBL] [Abstract][Full Text] [Related]
34. Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.
Hilhorst M; van Paassen P; Tervaert JW;
J Am Soc Nephrol; 2015 Oct; 26(10):2314-27. PubMed ID: 25956510
[TBL] [Abstract][Full Text] [Related]
35. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
36. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry.
Hruskova Z; Stel VS; Jayne D; Aasarød K; De Meester J; Ekstrand A; Eller K; Heaf JG; Hoitsma A; Martos Jimenéz C; Ravani P; Wanner C; Tesar V; Jager KJ
Am J Kidney Dis; 2015 Oct; 66(4):613-20. PubMed ID: 25975963
[TBL] [Abstract][Full Text] [Related]
38. The protein tyrosine phosphatase nonreceptor 22 C1858T polymorphism and vasculitis: a meta-analysis.
Lee YH; Choi SJ; Ji JD; Song GG
Mol Biol Rep; 2012 Aug; 39(8):8505-11. PubMed ID: 22696186
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: an unrecognized example of poliautoimmunity.
Martín-Nares E; Zuñiga-Tamayo D; Hinojosa-Azaola A
Clin Rheumatol; 2019 Jan; 38(1):97-106. PubMed ID: 30006919
[TBL] [Abstract][Full Text] [Related]
40. Genetics of ANCA-associated vasculitis in Japan: a role for HLA-DRB1*09:01 haplotype.
Tsuchiya N
Clin Exp Nephrol; 2013 Oct; 17(5):628-630. PubMed ID: 23180035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
